

75% of adult patients with HPP* suffer from pain, making it one of the most common symptoms¹



Neuropathic pain^{2,3}



Musculoskeletal pain^{1,4}

Rethink HPP disease burden especially the impact on daily function and QoL, and the potential for progression in children and adults⁵⁻⁷

*(N=160/213) Data from the Global HPP Registry, sponsored by Alexion Pharmaceuticals, an observational, longitudinal, multinational, long-term study collecting data on HPP diagnosis, history, clinical course, symptoms (including multisystemic aspects of disease) and burden of illness from patients who have a diagnosis of HPP.^{1,6} HPP, hypophosphatasia; QoL, quality of life.

1. Dahir KM, et al. *Orphanet J Rare Dis.* 2022;17(1):277.
2. Lehane F, et al. *J Clin Med.* 2024;13(8):2263.
3. Colazo JM, et al. *Osteoporos Int.* 2019;30(2):469–480.
4. Khan AA, et al. *Osteoporos Int.* 2024;35(3):431–438.
5. Rush ET, et al. *Orphanet J Rare Dis.* 2019;14(1):201.
6. Seefried L, et al. *J Bone Miner Res.* 2020;35(11):2171–2178.
7. Szabo SM, et al. *Orphanet J Rare Dis.* 2019;14(1):85.

The Alexion logo is a registered trademark of Alexion Pharmaceuticals, Inc.
This material is intended for healthcare professionals only.

© 2025 Alexion Pharmaceuticals, Inc. All rights reserved.

GL/UNB-H/0019 | February 2025

ALEXION[®]
AstraZeneca Rare Disease